迈威生物(688062.SH)：重新向香港联交所递交H股发行并上市的申请并刊发申请资料

Core Viewpoint - The company, Maiwei Biotech (688062.SH), has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on August 29, 2025 [1] Group 1 - The application was made in compliance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The submitted materials are in draft form and may be updated or revised as necessary [1] - Investors are advised not to make investment decisions based solely on the information contained in the application materials [1]